PEGMGF
PEGylated version of MGF (mechano-growth factor). No published studies of PEG-MGF itself were found; the non-PEGylated MGF E-peptide has limited mouse data with mixed cardiac effects.
Regulatory status (as of Sept 2026)
Slated for PCAC review before end of Feb 2027. Not currently eligible for 503A compounding; not FDA-approved.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
PEG-MGF is a compound studied only in animals and lab experiments so far. PEGylated version of MGF (mechano-growth factor).
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsNo published studies of PEG-MGF. Non-PEGylated MGF E-domain peptides were given to mice at 2.25-9 mg/kg/day for 2 weeks (Solís 2022, cardiac function), with mixed and dose-dependent effects.Community-reportedCommunity-reported: 200 mcg 2–3x per week, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is MGF with a chemical tail added to make it last longer in the blood; this has not been measured for PEG-MGF itself. Proposed mechanism: MGF with polyethylene glycol (PEG) attached, intended to extend circulation time. No pharmacokinetic study of PEG-MGF was found; PEGylation of a different molecule, IGF-I, extended its half-life to 140-200 h in a first-in-human study (Kletzl 2017).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedIn user communities, PEG-MGF is typically run at 200 mcg 2–3x per week (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| PEG-MGF | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| ACE-031 | ~12 days | Subcutaneous injection | Discontinued |
| Follistatin 344 | Unknown | Subcutaneous injection | Preclinical (animal) |
| IGF-1 DES | No published PK data found (des(1-3)IGF-I clears more rapidly than IGF-I in pigs/marmosets, but no published t1/2 value was found) | Intramuscular (site-specific) | Preclinical (animal) |
| IGF-1 LR3 | No published PK data found | Subcutaneous or intramuscular | Preclinical (animal) |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Muscle category. View All Muscle Peptides
Healing, Growth Hormone
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.